RXDX — Prometheus Biosciences Share Price
Last trade - 00:00- $9.56bn
- $8.85bn
- $6.81m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.7 | ||
| Price to Tang. Book | 13.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2,392.7 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.97% | ||
| Return on Equity | -33.3% | ||
| Operating Margin | -4064.71% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 1.12 | 1.23 | 3.13 | 6.81 | 4.15 | 3.75 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Prometheus Biosciences, Inc. is a clinical-stage biotechnology company. The Company discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.
Directors
- Tadataka Yamada NEC (75)
- Mark McKenna PRE (41)
- Keith Marshall CFO (53)
- Mark Stenhouse COO (54)
- Olivier Laurent CTO (49)
- Laurens Kruidenier CSO (51)
- Timothy Andrews GCN (42)
- Allison Luo OTH (48)
- James Laur DRC (60)
- Helen Adams IND (54)
- Martin Hendrix IND (53)
- Joseph Papa IND (65)
- Judith Swain IND (72)
- Mary Szela IND (58)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- October 26th, 2016
- Public Since
- March 11th, 2021
- No. of Shareholders
- 17
- No. of Employees
- 97
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 47,813,238
- Address
- 3050 Science Park Road, #342, SAN DIEGO, 92121
- Web
- https://www.prometheusbiosciences.com/
- Phone
- +1 8584224300
- Contact
- Noel Kurdi
- Auditors
- BDO USA, LLP
Upcoming Events for RXDX
Similar to RXDX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 01:17 UTC, shares in Prometheus Biosciences are trading at $199.92. This share price information is delayed by 15 minutes.
Shares in Prometheus Biosciences last closed at $199.92 and the price had moved by +692.7% over the past 365 days. In terms of relative price strength the Prometheus Biosciences share price has outperformed the S&P500 Index by +580.01% over the past year.
The overall consensus recommendation for Prometheus Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Prometheus Biosciences does not currently pay a dividend.
Prometheus Biosciences does not currently pay a dividend.
Prometheus Biosciences does not currently pay a dividend.
To buy shares in Prometheus Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $199.92, shares in Prometheus Biosciences had a market capitalisation of $9.56bn.
Here are the trading details for Prometheus Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: RXDX
Based on an overall assessment of its quality, value and momentum Prometheus Biosciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Prometheus Biosciences is $190.00. That is 4.96% below the last closing price of $199.92.
Analysts covering Prometheus Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$3.99 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prometheus Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +61.04%.
As of the last closing price of $199.92, shares in Prometheus Biosciences were trading +82.41% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Prometheus Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $199.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Prometheus Biosciences' management team is headed by:
- Tadataka Yamada - NEC
- Mark McKenna - PRE
- Keith Marshall - CFO
- Mark Stenhouse - COO
- Olivier Laurent - CTO
- Laurens Kruidenier - CSO
- Timothy Andrews - GCN
- Allison Luo - OTH
- James Laur - DRC
- Helen Adams - IND
- Martin Hendrix - IND
- Joseph Papa - IND
- Judith Swain - IND
- Mary Szela - IND